Latest Breaking News On - Heart valves - Page 7 : vimarsana.com
Heart Valves by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for Transcatheter Heart Valves
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Transcatheter Heart
Valves by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
New-yorkUnited-statesAustraliaJapanUnited-kingdomIranArgentinaBrazilChinaBostonMassachusettsCanadaPhotograph by Rajwant Rawat
On March 10, the $274 billion, Cupertino, California-based Apple Inc. announced it is starting production of the 5G-compatible iPhone 12 in India. It appeared like a routine announcement. After all, Apple has been assembling older generation iPhones in India through contract manufacturers since 2017. It wasn't.
It might have been a small step for Apple but was a giant leap for Indian manufacturing. India's new Production Linked Incentive (PLI) Scheme to reduce import dependence and promote local manufacturing had lured three of Apple's Taiwanese original equipment manufacturers - Foxconnn Hon Hai, Wistron and Pegatron - to pump in millions of dollars to expand Indian facilities. They will move a step up from assembling imported parts here to making or sourcing more components locally. Like Apple, about 70 firms have shown interest in availing the PLI Scheme to set up manufacturing facilities in three key sectors: mobile and electronic components; pharma-APIs (active pharmaceutical ingredients); KSM (key starting materials) and medical devices.
GurgaonHaryanaIndiaTaiwanSikriUttar-pradeshHimachal-pradeshPuducherryPondicherryNew-delhiDelhiChina Updated Feb 25, 2021 | 12:58 IST
With modern technology available the risks of replacement of the valve are minimal.Here is all you need to know about aortic valve replacement surgery. Heart diseases: Everything you need to know about aortic valve replacement surgery | Photo Credit: iStock Images
New Delhi: Aortic valve replacement surgery is a type of open-heart surgery to help tackle problems related to the heart’s aortic valve. During this surgery, one’s damaged valve is replaced with a new valve.
The aortic helps control the blood flow out from one’s heart to supply oxygenated blood to the rest of the body. Thus, it is the responsibility of the valves to maintain one-way blood flow via the heart. Are you aware? 4 valves are present in the heart including the mitral, tricuspid, aortic, and pulmonic valves. Moreover, the aortic valve is situated between one’s left ventricle (heart pumping chamber) and the aorta (the largest artery in the body).
MumbaiMaharashtraIndiaNew-delhiDelhiBipeenchandra-bhamreSir-hn-reliance-foundation-hospitalResearch-centrePhoto-creditStock-imagesCardiothoracic-surgeonAortic-valve-replacementLivaNova PLC: LivaNova Reports Fourth Quarter and Full-Year 2020 Results
LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020.
For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percent on a reported basis and a decline of 7.7 percent on a constant-currency
1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), fourth quarter 2020 diluted loss per share from continuing operations was $5.74. Fourth quarter 2020 adjusted diluted earnings per share from continuing operations was $0.71.
ItalyUnited-statesCanadaLondonCity-ofUnited-kingdomMelissa-farinaDamien-mcdonaldExchange-commissionSecurities-exchangeAccepted-accounting-principlesChief-executive-officerOperator
Good day, ladies and gentlemen, and thank -- and welcome to the LivaNova PLC Fourth Quarter and Full Year 2020 Earnings Conference Call. [Operator Instructions]
I would now like to introduce your host for today's conference, Mr. Matthew Dodds, LivaNova's Senior Vice President of Corporate Development. Please go ahead, sir.
Matthew Dodds --
Senior Vice President, Corporate Development
Thank you, Catherine. And welcome to our conference call and webcast discussing LivaNova's financial results for the fourth quarter and full year 2020. Joining me on today's call are Damien McDonald, our Chief Executive Officer; Alex Shvartsburg, our Interim Chief Financial Officer; and Melissa Farina, our Vice President of Investor Relations.
HoustonTexasUnited-statesItalyAustraliaJapanCanadaSaluggiaPiemonteSpainMike-matsonAdam-maeder-piper-sandlerShare:
ResearchAndMarkets.com's offering.
The global biomaterials market is projected to reach USD 47.5 billion by 2025 from USD 35.5 billion in 2020, at a CAGR of 6.0% during the forecast period.
Growth in this market is primarily attributed to increasing funds and grants by government bodies and universities for the development of novel biomaterials, increasing demand for implantable devices, growing demand for biomaterials in plastic surgery and wound healing applications, rising incidences of cardiovascular diseases, and rising awareness and research on regenerative medicine.
By metallic biomaterials segment, the Titanium & Titanium Alloys segment accounted for the fastest-growing segment of the biomaterials market.
On the basis of type, the metallic biomaterials are further segmented as Stainless Steel, Titanium & Titanium Alloys, Cobalt-Chrome Alloys, Gold, Silver, and Magnesium. the titanium & Titanium Alloy accounted for the fastest-growing segment of the metallic biomaterials segment. sThese biomaterials do not show any form of toxicity or allergic reactions on contact with the body. Additionally, factors such as excellent biocompatibility, corrosion resistance, the balance of mechanical properties, and low weight stimulate the demand for titanium-based biomaterials.
ChinaBerkeleyCaliforniaUnited-statesJapanIndiaCanadaDublinIrelandAmericaCeramtec-gmbAsia-pacific
Based on application, the cardiovascular application market is categorized into nine sub-segments— Catheters, Stents, Implantable Cardiac Defibrillators, Pacemakers, Sensors, Heart Valves, Vascular Grafts, Guidewires, and Other products. Catheters accounted for the largest share of the cardiovascular application segment due to the shift in patient preference from traditional open surgeries to minimally invasive surgeries.
The Asia Pacific region is estimated to grow at the highest CAGR in the biomaterials market during the forecast period, this is mainly due to Japan’s growing healthcare industry, increasing geriatric population, rising number of cosmetic and plastic surgeries in India, lucrative medical devices industry, and favorable tax policies in China.
ChinaBerkeleyCaliforniaUnited-statesJapanIndiaNetherlandsNoble-biomaterials-incArtoss-incOlympus-terumo-biomaterials-corporation-japanEvonik-industries-germany